These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28753810)

  • 61. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
    Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
    J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
    Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer.
    Krzyzanowska A; Barron S; Higgins DF; Loughman T; O'Neill A; Sheehan KM; Wang CA; Fender B; McGuire L; Fay J; O'Grady A; O'Leary D; Watson RW; Bjartell A; Gallagher WM
    Eur Urol Focus; 2023 Nov; 9(6):983-991. PubMed ID: 37105783
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
    Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
    Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.
    Brajtbord JS; Leapman MS; Cooperberg MR
    Eur Urol; 2017 May; 71(5):705-709. PubMed ID: 27616723
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
    Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
    Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
    Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.
    Joniau S; Briganti A; Gontero P; Gandaglia G; Tosco L; Fieuws S; Tombal B; Marchioro G; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; Van Poppel H; Spahn M;
    Eur Urol; 2015 Jan; 67(1):157-164. PubMed ID: 24486307
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
    Chang JH; Park W; Park JS; Pyo H; Huh SJ; Choi HY; Lee HM; Jeon SS; Seo SI
    Int J Urol; 2015 Jan; 22(1):82-7. PubMed ID: 25208624
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.